Click Here to View the program in Japanese

The world surrounding cancer treatment continues to evolve rapidly. New, emerging products include not only immuno-oncology drugs, but also regenerative medicine and medical devices, that expand the therapeutic choice in the field of cancer treatment. There are plenty of new topics, such as the remarkable progress of genome analysis technology toward truly personalized medicine, new regulatory frameworks of accelerated approval and Sakigake designation, proposals of innovative clinical trial designs that enable evidence building for rare cancers, better utilization of real world data, and many more. Thanks to the rapidly evlolving digital applications, artificial intelligence (AI), and the Internet of Things (IoT) that affect clinical trial operations, clinical development faces both challenge and opportunity to keep the evaluation of  novel therapeutic products simple and reliable. In addition, as clinical trials are increasingly recognized as a part of “Patients’s Journey”, the demand for improvement of access to the cancer clinical trials has become stronger.

What are we supposed to do in the face of such tide of rapid change in this field? What can we do for the patients in the world who are facing and battling cancer daily? There are growing number of people who disclose that they are cancer patients and influence the public’s image, knowledge and expectations of cancer and its treatment by sharing their story of daily struggles and experiences. Clearly, there is a need for a new stage of discussion on various aspects of potential progress in cancer treatment from a new perspective, free from biased views based on our past successes.